DTIL News
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical...
Business Wire
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a...
Business Wire
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a...
Business Wire
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced changes to its senior leadership team. Alex Kelly, currently Chief Financial...
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precisions Board of Directors...
Business Wire
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000 Index, effective at the close of U.S. equity...
Business Wire
Why Is Precision BioSciences Stock Gaining Wednesday?
Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.read more...
Benzinga
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study...
Business Wire
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will host an investor webcast to discuss new biopsy and clinical data from...
Business Wire